Overview

A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

Status:
Not yet recruiting

Trial end date:
2025-09-30

Target enrollment:

Participant gender:

Summary

To find a recommended dose of attIL2-T cell therapy that can be given to patients with soft tissue or bone sarcomas and to see if it can help to control the disease.

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Cyclophosphamide